Real-world Data Market Worth $2 Billion by 2029 – Exclusive Report by Meticulous Research®


Redding, California, June 21, 2022 (GLOBE NEWSWIRE) — According to a new market research report titled, Real-world Data Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post-market Surveillance], and End User (Pharma, Payers) – Global Forecast to 2029”, published by Meticulous Research®, the real-world data market is expected to grow at a CAGR of 8.2% from 2022 to 2029, to reach $2 billion by 2029.

Download Free Sample Report Now @

Real-world data drives healthcare and research discussions & decisions by providing evidence that regulators, payers, and providers demand. RWD is used by pharmaceutical, biotechnology, & medical device companies; healthcare payers; healthcare providers; and other end users (academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies) to add value at every stage of the drug development lifecycle from understanding unmet healthcare needs and defining the patient journey to supporting regulatory submissions and post-market studies, offering value to payers, and defining market strategies. The growth of this market is driven by key factors such as rapidly growing big data in healthcare, shift from volume to value-based care, growing adoption of artificial intelligence (AI) in RWD studies, and rising focus on personalized healthcare.

Impact of COVID-19 on the Real World Data Market

The key players operating in the RWD market experienced an initial shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was due to significant restrictions on travel in many countries, shifting resources on COVID-19 treatments in healthcare settings, and limited hospital access. These factors affected the amount of real-world data generated globally. However, after the initial shrinkage, the RWD is set to become the most influential emerging technology to fight against the COVID-19 outbreak. Real-world data can provide valuable insights to understand better, monitor, and prepare for the challenges caused by the COVID-19 pandemic. RWD has been used increasingly to map the disease’s progression and discover vaccines and immediate treatments. Thus, the effectiveness of RWD was significantly impacted during the pandemic and continues to play a significant role in infection treatment.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:

RWD market: Future Outlook

The global RWD market is segmented based on Source (EMR/EHR/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Genomics Data, and Other Datasets), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post-market Surveillance, Medical Device Development & Approvals, and regulatory and clinical decision-making), End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users), and Geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market share at the global and regional levels.

Based on source, in 2022, the EMR/EHR/clinical data segment is estimated to account for the largest market share of the RWD market, owing to the significant amounts of data generated in hospitals, the increasing adoption of EHR/EMR in hospitals, and the increased use of clinical data for RWE generation. However, the pharmacy data segment is projected to show the fastest growth rate during the forecast period. The evolution of the pharmaceutical industry due to the increasing geriatric population and cases of chronic diseases have increased the R&D departments’ burden of developing disease-specific medications such as oncological and neurological drugs. The development of pharmaceutical drugs requires evidence-based data to understand disease epidemiology, patient journey, real-world use, the effectiveness of treatment options, unmet patient needs, and the value that products offer in sub-populations. The increasing amount of pharmacy data and growing focus on e-prescriptions can serve as a real-world data source to help guide local commercial strategic planning and market access strategy, provide data-driven insights to aid the payers’ and HTAs’ decision-making, maximize payer coverage, and improve patient outcomes.

Quick Buy – Real-world Data (RWD) Market Research Report:

Based on application, in 2022, the market access & reimbursement/coverage decisions segment is estimated to account for the largest market share of the RWD market. The large market share of this segment is primarily attributed to the increasing demand for real-world data to accelerate drug discovery & development and deliver a value-based price. However, the drug development & approvals segment is projected to show the fastest growth rate during the forecast period. Factors attributing to the growth of this segment are increasing demand for real-world data to enhance drug discovery and development and increasing investments by biopharmaceutical companies in R&D. In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common clinical trial elements. The real-world data is regularly utilized to inform aspects of drug development. The adoption of AI in drug development & approval processes is also driving the demand for RWD. AI integrated RWD studies are conducted in various stages of the drug development process, such as for designing clinical trials, modeling, and forecasting patient enrichment and recruitment using multiple RWD sources, selecting investigator sites, patient monitoring & managing and medication adherence & retention, market access, and post-market surveillance.

Based on end user, the pharmaceutical, biotechnology, and medical device companies segment is projected to show the fastest growth rate during the forecast period. Rising pharmaceutical R&D spending is attributed to the growth of this segment. The cost of developing a new drug was more than USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face. The global R&D spending in 2021 surged by 7.0% (USD 212 billion) compared to 2020. Real-world data helps understand real-life clinical practices and actual health outcomes of drugs. It also helps generate broader scientific evidence and commercial insights, valuable for the pharmaceutical industry.

Based on geography, in 2022, North America is expected to command the largest market share of the real-world data market. This region’s large market share is attributed to the increasing prevalence of chronic diseases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, availability of electronic datasets, advanced healthcare industry, and rising big data in healthcare. The adoption of EHRs in hospitals and patient registries is boosting the RWD market in North America. Basic EHR adoption has increased in the U.S. from 27.9% in 2010 to nearly 86% in 2017. As of 2021, around 94% of the hospitals in the US already have EHR or are in the process of adopting EHR.

Key companies operating in the global RWD Market are Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here:

Scope of the Report

RWD Market, by Source

  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Genomics Data
  • Other Datasets

(Note – The Other Datasets segment majorly includes data generated from mobile devices, wearable devices, and social media)

RWD Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post-market Surveillance
  • Medical Device Development & Approvals
  • Regulatory and Clinical Decision-Making

(Note – Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

RWD Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note – Other End Users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWD Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Singapore
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Download Free Sample Report Now @

Related Reports:

Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) – Global Forecast to 2028

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) – Forecast to 2028

RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post Market Surveillance), End User (Pharma, Payer, Provider) – Global Forecast to 2029

Healthcare IT Market by Product (EMR, mHealth, PHM, RIS, PACS, RCM, Healthcare Analytics, Telehealth, SCM, HIE), Component (Software, Service), Delivery Mode (Web, Cloud) and End User (Hospital, Payer, Pharmacy, Ambulatory, Homecare) – Global Forecast to 2027

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Type, Practice Size (Large, Small-to-medium, Solo), Application (Patient Portals, Practice Management, CDS, Computerized Physician Order Entry, PHM), and End User – Global Forecast to 2028

Mid-revenue Cycle Management/ Clinical Documentation Improvement Market by Product & Service [Solutions (Coding, Charge Capture, DRG Group, Pre-Bill Review), Consulting Services], End User (Providers, Payers), and Geography – Global Forecast to 2027

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding, 
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- [email protected] 
Visit Our Website:
Connect with us on LinkedIn-
Content Source: